A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer

The purpose of this prospective phase II clinical trial was to investigate the efficacy and safety of anlotinib in patients with relapsed small cell lung cancer (SCLC). Forty‐five patients with relapsed SCLC were enrolled and treated with anlotinib (one cycle of 12 mg daily for 14 days, discontinued...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Cancer
Main Authors: Wu, Di, Nie, Jun, Hu, Weiheng, Dai, Ling, Zhang, Jie, Chen, Xiaoling, Ma, Xiangjuan, Tian, Guangming, Han, Jindi, Han, Sen, Long, Jieran, Wang, Yang, Zhang, Ziran, Fang, Jian
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Cancer Therapy and Prevention
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7689882/
https://ncbi.nlm.nih.gov/pubmed/32557583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.33161
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados